Longitudinal Outcomes of COVID-19 in Solid Organ Transplant Recipients from 2020 to 2023
Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved..
Data regarding COVID-19 outcomes in solid organ transplant recipients(SOTr) across SARS-CoV-2 waves, including the impact of different measures, is lacking. This cohort study, conducted from March 2020-May 2023 in Toronto, Canada, aimed to analyze COVID-19 outcomes in 1,975 SOTr across various SARS-CoV-2 waves and assess the impact of preventive and treatment measures. The primary outcome was severe COVID-19, defined as requiring supplemental oxygen, with secondary outcomes including hospitalization, length of stay, ICU admission, and 30-day and 1-year all-cause mortality. SARS-CoV-2 waves were categorized as Wildtype/Alpha/Delta(318 cases, 16.1%), Omicron-BA.1(268, 26.2%), Omicron-BA.2(268, 13.6%), Omicron-BA.5(561, 28.4%), Omicron-BQ.1.1(188, 9.5%), and Omicron-XBB.1.5(123, 6.2%). Severe COVID-19 rate was highest during the Wildtype/Alpha/Delta wave(44.6%), and lower in Omicron waves(5.7-16.1%). Lung transplantation was associated with severe COVID-19(OR:4.62, 95%CI:2.71-7.89), along with rituximab treatment(OR:4.24, 95%CI:1.04-17.3), long-term corticosteroid use(OR:3.11, 95%CI:1.46-6.62), older age(OR: 1.51, 95%CI:1.30-1.76), chronic lung disease(OR:2.11, 95%CI:1.36-3.30), chronic kidney disease(OR:2.18, 95%CI:1.17-4.07), and diabetes(OR:1.97, 95%CI:1.37-2.83). Early treatment and ≥3 vaccine doses were associated with reduced severity(OR: 0.29, 95%CI:0.19-0.46, and 0.35, 95%CI:0.21-0.60, respectively). Tixagevimab/cilgavimab and bivalent boosters did not show a significant impact. The study concludes that COVID-19 severity decreased across different variants in SOTr. Lung transplantation was associated with worse outcomes and may benefit more from preventive and early therapeutic interventions.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
---|---|
Enthalten in: |
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons - (2024) vom: 16. März |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Solera, Javier T [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Revised 18.03.2024 published: Print-Electronic Citation Status Publisher |
---|
doi: |
10.1016/j.ajt.2024.03.011 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM369887360 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM369887360 | ||
003 | DE-627 | ||
005 | 20240319233452.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240319s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.ajt.2024.03.011 |2 doi | |
028 | 5 | 2 | |a pubmed24n1336.xml |
035 | |a (DE-627)NLM369887360 | ||
035 | |a (NLM)38499087 | ||
035 | |a (PII)S1600-6135(24)00207-7 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Solera, Javier T |e verfasserin |4 aut | |
245 | 1 | 0 | |a Longitudinal Outcomes of COVID-19 in Solid Organ Transplant Recipients from 2020 to 2023 |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 18.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status Publisher | ||
520 | |a Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
520 | |a Data regarding COVID-19 outcomes in solid organ transplant recipients(SOTr) across SARS-CoV-2 waves, including the impact of different measures, is lacking. This cohort study, conducted from March 2020-May 2023 in Toronto, Canada, aimed to analyze COVID-19 outcomes in 1,975 SOTr across various SARS-CoV-2 waves and assess the impact of preventive and treatment measures. The primary outcome was severe COVID-19, defined as requiring supplemental oxygen, with secondary outcomes including hospitalization, length of stay, ICU admission, and 30-day and 1-year all-cause mortality. SARS-CoV-2 waves were categorized as Wildtype/Alpha/Delta(318 cases, 16.1%), Omicron-BA.1(268, 26.2%), Omicron-BA.2(268, 13.6%), Omicron-BA.5(561, 28.4%), Omicron-BQ.1.1(188, 9.5%), and Omicron-XBB.1.5(123, 6.2%). Severe COVID-19 rate was highest during the Wildtype/Alpha/Delta wave(44.6%), and lower in Omicron waves(5.7-16.1%). Lung transplantation was associated with severe COVID-19(OR:4.62, 95%CI:2.71-7.89), along with rituximab treatment(OR:4.24, 95%CI:1.04-17.3), long-term corticosteroid use(OR:3.11, 95%CI:1.46-6.62), older age(OR: 1.51, 95%CI:1.30-1.76), chronic lung disease(OR:2.11, 95%CI:1.36-3.30), chronic kidney disease(OR:2.18, 95%CI:1.17-4.07), and diabetes(OR:1.97, 95%CI:1.37-2.83). Early treatment and ≥3 vaccine doses were associated with reduced severity(OR: 0.29, 95%CI:0.19-0.46, and 0.35, 95%CI:0.21-0.60, respectively). Tixagevimab/cilgavimab and bivalent boosters did not show a significant impact. The study concludes that COVID-19 severity decreased across different variants in SOTr. Lung transplantation was associated with worse outcomes and may benefit more from preventive and early therapeutic interventions | ||
650 | 4 | |a Journal Article | |
700 | 1 | |a Árbol, Berta G |e verfasserin |4 aut | |
700 | 1 | |a Mittal, Ankit |e verfasserin |4 aut | |
700 | 1 | |a Hall, Victoria |e verfasserin |4 aut | |
700 | 1 | |a Marinelli, Tina |e verfasserin |4 aut | |
700 | 1 | |a Bahinskaya, Ilona |e verfasserin |4 aut | |
700 | 1 | |a Selzner, Nazia |e verfasserin |4 aut | |
700 | 1 | |a McDonald, Michael |e verfasserin |4 aut | |
700 | 1 | |a Schiff, Jeffrey |e verfasserin |4 aut | |
700 | 1 | |a Sidhu, Aman |e verfasserin |4 aut | |
700 | 1 | |a Humar, Atul |e verfasserin |4 aut | |
700 | 1 | |a Kumar, Deepali |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons |d 2001 |g (2024) vom: 16. März |w (DE-627)NLM119667924 |x 1600-6143 |7 nnns |
773 | 1 | 8 | |g year:2024 |g day:16 |g month:03 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ajt.2024.03.011 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2024 |b 16 |c 03 |